Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities
Open accessThe DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Abstract
Chronic and excessive inflammation in skin and joints causes significant morbidity in psoriasis patients. As a prevalent T lymphocyte-mediated disorder, psoriasis, as well as the side effects associated with its treatment, affects patients globally. In this review, recent progress is discussed in the areas of genetics, the immunological synapse, the untangling of the cytokine web and signaling pathways, xenotransplantation models, and the growing use of selectively targeted therapies. Since psoriasis is currently incurable, new management strategies are proposed to replace previous serendipitous approaches. Such strategic transition from serendipity to the use of novel selective agents aimed at defined targets in psoriatic lesions is moving rapidly from research benches to the bedsides of patients with this chronic and debilitating disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The development of psoriatic plaques is accompanied by activation of CD4 + T cells and other immune cells, which provide a plethora of cytokines and chemokines, including TNF and IFNγ 136”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [136]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205 · cited 1×
“in keratinocytes to create a “danger signal” is unclear (51), but several possible molecular events may occur to activate resting dendritic APCs (52), followed by delivery of an antigenic signal”
BackgroundPoints of control in inflammation
Nathan, C. (2002) · Nature · doi:10.1038/nature01320 · Cited by 2,738 · cited 1×
“ic inflammatory diseases, HMGB1 is also considered an important regulator (67).”
BackgroundHuman epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP
Soumelis, V., Reche, P. A., Kanzler, H., Yuan, W., Edward, G., Homey, B., Gilliet, M., Ho, S., Antonenko, S., Lauerma, A., et al. (2002) · Nature Immunology · doi:10.1038/ni805 · Cited by 2,183 · cited 10×
“The successful use of cyclosporin, which acts to block cytokine release, resulted in a paradigm shift away from epidermal keratinocytes to various immunocyte populations including T cell subsets and dendritic APCs.”
BackgroundInfluentialAggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446 · cited 1×
“binds TNF-α and improves psoriatic arthritis and skin lesions (93, 94); and onercept, which improves Crohn disease (95).”
Backgroundp38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases
Kumar, S., Boehm, J., & Lee, J. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1177 · Cited by 1,197 · cited 1×
“small molecules that can interfere with inflammatory responses mediated by p38 signaling (106), cytokine receptors (107), or rationally designed dominant negative TNF-α variants (108).”
BackgroundEtanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175 · cited 1×
“binds TNF-α and improves psoriatic arthritis and skin lesions (93, 94); and onercept, which improves Crohn disease (95).”
BackgroundWeitz-Schmidt, G., Welzenbach, K., Brinkmann, V., Kamata, T., Kallen, J., Bruns, C., Cottens, S., Takada, Y., & Hommel, U. (2001) · Nature Medicine · doi:10.1038/89058 · Cited by 1,041
Cited by
Items 401–500 of 542
Hertz, A. (2014) · Revista Hospital Universitário Pedro Ernesto · doi:10.12957/rhupe.2014.12250 · Cited by 4
Plantar Psoriasis Associated with Olmesartan
Charfi, O., Badri, T., Lakhoua, G., Kastalli, S., Aïdli, S. E., & Zaïem, A. (2018) · Current Drug Safety · doi:10.2174/1574886313666181017120629 · Cited by 4
A mentally challenged adult with tonic convulsions, dysmorphic face and sebopsoriasis.
John, M., Sudeep, K., Thomas, N., & Thomas, M. (2006) · PubMed · Cited by 4
Very late antigen‐1 in psoriasis: an immunohistochemical study
Baum, S., Barzilai, A., Huszar, M., Greenberger, S., Trau, H., & Bank, I. (2007) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2007.02402.x · Cited by 4
Kandil, A. H., Salem, A., Nasar, A., Farag, R. M. A., & ElKashishy, K. (2014) · Egyptian Journal of Dermatology and Venerology · doi:10.4103/1110-6530.137262 · Cited by 4
Arkhypkina, T. L., & Lyubimovа, L. P. (2016) · Obstetrics Gynecology and Reproduction · doi:10.17749/2313-7347.2016.10.2.024-028 · Cited by 4
Negrei, C., & Boda, D. (2017) · InTech eBooks · doi:10.5772/67793 · Cited by 4
Other Approved Therapeutic Monoclonal Antibodies
Baldo, B. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-30472-4_4 · Cited by 3
EVALUATION OF PSORIASIS TREATMENT WITH ESOMEPRAZOLE - A PILOT STUDY
Bafutto, M., de Oliveira, Ê. C., & Zaterka, S. (2019) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.201900000-49 · Cited by 3
Pathophysiology of Psoriasis/Novel Pathways
Hugh, J. M., & Weinberg, J. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-54859-9_2 · Cited by 3
Mohammed, T. M., Mutlag, S. H., & Al-Baghdady, B. A. S. (2020) · Iraqi Journal of Pharmaceutical Sciences · doi:10.31351/vol29iss2pp176-184 · Cited by 3
“Psoriasis can start at any age, although epidemiological studies suggested that it can most commonly occur for the first time between the ages of 15 and 25.((4)) Moreover, its prevalence estimates vary from 0.”
BackgroundWei, L., & Zhao, Y. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s40638 · Cited by 4
“There is a rise in the infiltration and expansion of several types of leukocytes and in the number of inflammatory dendritic cells and plasmacytoid dendritic cells.(21) Keratinocytes also increase leukocyte trafficking into diseased tissue by greater synthesis of S100 proteins in psoriasis.”
InfluentialAl-Shamma, G. A. A., Ahmed, Y. N., & Hassen, A. S. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs22164940 · Cited by 3
Psoriasis as a Chess Board — An Update of Psoriasis Pathophysiology
Robyn, S., Mitra, A., Morrisey, L., & Lim, H. (2013) · InTech eBooks · doi:10.5772/53580 · Cited by 8
“This is part of the working model of the immune synapse of T cells in psoriasis, integrating T cell signaling pathways in autoimmunity [29].”
BackgroundPsoriasis Vulgaris and Arthopathica
Jacobi, A., & Prinz, J. C. (2011) · Springer eBooks · doi:10.1007/978-3-211-99225-8_14 · Cited by 3
Prospects for Vaccines for Allergic and Other Immunologic Skin Disorders
Medi, B. M., & Singh, J. (2006) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200607030-00001 · Cited by 3
Mahiques, L., Pitarch, G., Sánchez‐Carazo, J. L., Pérez‐Ferriols, A., Soriano, C. J., & Alegre, V. A. (2007) · Actas Dermo-Sifiliográficas · doi:10.1016/s0001-7310(07)70129-1 · Cited by 3
Developments in psoriasis and psoriatic arthritis
Feletar, M., Foley, P. A., & Brown, M. A. (2008) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2008.05.001 · Cited by 4
Nagui, N. A. R., Hay, R. M. A., & Rashed, L. (2012) · Journal of the Egyptian Womenʼs Dermatologic Society · doi:10.1097/01.ewx.0000407877.24678.ef · Cited by 3
Akbaba, H. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.90334 · Cited by 4
Kutty, P. K., & Kutty, M. K. (2021) · Springer eBooks · doi:10.1007/978-981-33-6408-0_3 · Cited by 3
Immunomorphology and Morphogenesis of Affected Skin Foci at Psoriasis
Kubanova, A. A., & Katunina, O. R. (2010) · Vestnik dermatologii i venerologii · doi:10.25208/vdv839 · Cited by 5
Chemokine Receptors in Inflammatory Diseases
Kraneveld, A. D., Braber, S., Overbeek, S. A., de Kruijf, P., Koelink, P. J., & Smit, M. J. (2010) · Methods and principles in medicinal chemistry · doi:10.1002/9783527631995.ch6 · Cited by 4
The problem with upward mobility
Gudjonsson, J. E., & Elder, J. T. (2007) · Nature Medicine · doi:10.1038/nm0707-786 · Cited by 3
Ionic liquids in dermatological drug delivery: advances, mechanisms, and therapeutic potential
Krishnan, A. M., Wairkar, S., & Pawar, B. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126603 · Cited by 2
Mustafa, A. I., Ibrahim, S. E., Gohary, Y. M., Alhusseini, N. F., Fawzy, E. M., & El-Shimi, O. S. (2021) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.14434 · Cited by 2
Krzistetzko, J., Géraud, C., Dormann, C., Riedel, A., & Leibing, T. (2024) · FEBS Open Bio · doi:10.1002/2211-5463.13857 · Cited by 2
Psoriasis: revisión del tema con énfasis en la inmunopatogénesis
Sierra, C., & Lopera, M. M. V. (2009) · IATREIA · doi:10.17533/udea.iatreia.8421 · Cited by 2
Viguier, M. A., Jeanmougin, M., Bégon, E., VEROLA, O., Dubertret, L., & Bachelez, H. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08041.x · Cited by 2
TaiHua, L., Liu, D., Chen, Y., Hu, Z., Chen, L., Luo, C., & Xu, Z. (2009) · 中国人民解放军军医大学学报:英文版 · doi:10.1016/s1000-1948(09)60013-7 · Cited by 2
Mahiques, L., Pitarch, G., Sánchez‐Carazo, J. L., Pérez‐Ferriols, A., Soriano, C. J., & Alegre, V. A. (2007) · Actas Dermo-Sifiliográficas · doi:10.1016/s1578-2190(07)70509-7 · Cited by 2
Determinants of psoriatic arthritis in patients with psoriasis
Queiró, R., Alpéri, M., Alonso, S., Riestra, J. L., & Ballina, J. (2010) · Expert Review of Dermatology · doi:10.1586/edm.09.69 · Cited by 2
SERUM LEVEL OF IL-17, IL-22, IFN- ,1 3$7,(176 :,7+ PSORIASIS
Almakhzangy, I., & Gaballa, A. (2009) · Cited by 7
Mucocutaneous candidiasis or psoriasis? A case report
Armin, S., Chavoshzadeh, Z., Karimi, A., Tajeddini, A., & Toosi, P. (2007) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 2
Azathioprine pulse therapy to prolong remission of psoriasis
Gupta, R. (2016) · Global Dermatology · doi:10.15761/god.1000153 · Cited by 2
Novel Insight Into the Role of Antimicrobial (Host Defense) Peptides/Proteins in Human Skin Diseases
Niyonsaba, F. (2016) · Juntendō Igaku/Juntendo igaku · doi:10.14789/jmj.62.120 · Cited by 2
Frers, R. A. K., Losada, M. E. O., Kersberg, E., Cosentino, V. L., & Capani, F. (2017) · InTech eBooks · doi:10.5772/intechopen.68559 · Cited by 2
“Serum and epidermal levels [105, 106] of TGF-β in Ps patients are associated with Ps disease severity [112, 113] and are diminished in low Ps [5].”
BackgroundJindal, S., Awasthi, R., Singare, D. S., & Kulkarni, G. T. (2021) · PLANT ARCHIVES · doi:10.51470/plantarchives.2021.v21.s1.308 · Cited by 2
GENETIC STUDY OF PSORIASIS DISEASE : A REVEIEW
AL-Sariay, A. H., Al‐Ahmer, S. D., Muslim, A. M., Abood, Z. H., & Haleem, H. (2021) · PLANT ARCHIVES · doi:10.51470/plantarchives.2021.v21.s1.335 · Cited by 2
“This disease can affect any race and can occur at any age and recognized by change proliferation and differentiation keratinocytes (Nickoloff and Nestle, 2004).”
Khalid, H. N., Gayed, E. M. A. E., Elrsool, A. M. A., & Bazid, H. A. S. (2021) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.14182 · Cited by 2
Immunomodulatory Effect of Methotrexate Abruptly Controls Keratinocyte Activation in Psoriasis
Elango, T., Jeyaraj, A., Dayalan, H., Gnanaraj, P., Li, X., & Zhang, X. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102811 · Cited by 2
Arshad, M., Kumar, A., Rehman, M. S. U., Rodriguez, P. R. T., & Varrassi, G. (2024) · Cureus · doi:10.7759/cureus.52139 · Cited by 2
[The pathogenesis of inflammatory dermatoses, especially psoriasis].
Bos, W., Thio, H. B., Neumann, H. A. M., van der Fits, L., & Prens, E. P. (2006) · PubMed · Cited by 2
The Study of Serum Complement C3, C4 and Immunoglobulin E IgE in Psoriasis Patients
Journal, B. S., Hussein, T. A., & Fadheel, B. M. (2015) · Baghdad Science Journal · doi:10.21123/bsj.12.4.708-714 · Cited by 3
Pharmacological Challenge Models in Clinical Drug Developmental Programs
Assil, S., Rißmann, R., & van Doorn, M. B. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85352 · Cited by 4
“Also, the nails and joints ( psoriatic arthritis) can be affected [44, 45].”
BackgroundSkin: Immunological Defence Mechanisms
Shiu, J., Harberts, E. M., Gaspari, A. A., & Nickoloff, B. J. (2013) · Wiley eBooks · doi:10.1002/9780470015902.a0001215.pub3 · Cited by 2
Self-citationTargeting the IL-12/IL-23 cytokine family in the treatment of psoriatic disease
Vergou, T., Lima, X. T. V., & Kimball, A. B. (2008) · Expert Review of Dermatology · doi:10.1586/17469872.3.4.453 · Cited by 2
What's New in Laboratory Research?
Pincelli, C., & Lotti, R. (2009) · Journal of Rheumatology Supplement · doi:10.3899/jrheum.090213 · Cited by 2
Tratamiento de la psoriasis en placas moderada y grave con fármacos biológicos
Casanova, J. M., Pujol, R. M., & Ribera, M. (2008) · Piel · doi:10.1016/s0213-9251(08)75124-4 · Cited by 2
The Role of Interleukin 12 in Iraqi Patients with Psoriasis
Abbas, E. A., & Mousa, H. M. (2022) · University of Thi-Qar Journal of Science · doi:10.32792/utq/utjsci.v9i1.873 · Cited by 1
“Psoriasis disorders may be induced by an inappropriate immune response to unknown causative factors, such as "autoantigen" or "bacteria," in which white blood cells are attracted and stimulated at the regions of inflamed tissue, hence exacerbating the condition (Nickoloff and Nestle, 2004) .”
BackgroundMehta, K. S., Negi, R., Chauhan, P. S., Sharma, A., Sharma, R., & Mahajan, V. K. (2023) · IP Indian Journal of Clinical and Experimental Dermatology · doi:10.18231/j.ijced.2023.022 · Cited by 1
Psoriasis vulgaris: von der Pathogenese zur Therapie
Yawalkar, N., & Braathen, L. R. (2006) · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · doi:10.4414/smf.2006.05885 · Cited by 1
The Role of Immune Response and the Impact of Biological Drugs in Psoriasis Patients
Amedei, A., & Milco, M. (2012) · InTech eBooks · doi:10.5772/25873 · Cited by 1
“A cluster of these adipokines is represented by pro-inflammatory cytokines (TNF-, IL-8 and IL-6) whose overproduction drives the psoriasis pathogenesis, as well as of certain basic features of MS like insulin resistance and diabetes (Arican et al., 2005; Nickoloff & Nestle, 2004; Rondinone, 2006).”
BackgroundInsights into the Pathogenesis and Treatment of Psoriasis
Robyn, S., Mitra, A., & Hermenio, C. (2012) · InTech eBooks · doi:10.5772/25844 · Cited by 2
Autoantikörper bei Patienten mit Psoriasis unter Anti‐TNF‐α‐Therapie
Bardazzi, F., Odorici, G., Virdi, A., Antonucci, V. A., Tengattini, V., Patrizi, A., & Balestri, R. (2014) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.12339_suppl · Cited by 1
HLA-Cw and TCR vβ analysis in twenty Mexican patients with psoriasis
Santos, L., León‐Galván, M. F., Fuentes‐Ahumada, C., Marino-Marmolejo, E. N., León‐Rodríguez, A. D., de la Rosa, A. P. B., Ceballos-Salazar, R., Torres‐Álvarez, B., & Moncada-González, B. (2011) · Open Medicine · doi:10.2478/s11536-011-0038-9 · Cited by 1
Ustekinumab for the treatment of plaque psoriasis
Reich, K. (2009) · Expert Review of Dermatology · doi:10.1586/edm.09.38 · Cited by 1
Función efectora de linfocitos T CLA+ sobre queratinocitos autólogos en psoriasis
Ferrán, M., Giménez‐Arnau, A. M., Bellosillo, B., Pujol, R. M., & Santamaria‐Babí, L. F. (2008) · Actas Dermo-Sifiliográficas · doi:10.1016/s0001-7310(08)76174-x · Cited by 1
Psoriasis Vulgaris’te Serum Galektin-3 Düzeyleri ve Hastalık Şiddeti ile İlişkisi
Özden, M. G., Denizli, H., Çaycı, Y. T., Çoban, A. Y., Aydın, F. Y., Şentürk, N., Cantürk, T., & Turanlı, A. Y. (2011) · TURKDERM · doi:10.4274/turkderm.82713 · Cited by 1
Mechanistic Insights Into Today’s (and Tomorrow’s) Treatments for Moderate-to-Severe Psoriasis
Young, M. S., & Kucera, K. J. (2016) · Journal of the Dermatology Nurses’ Association · doi:10.1097/jdn.0000000000000186 · Cited by 1
“…the underlying pathogenesis of psoriasis, biologics have been, and continue to be, developed based on scientific evidence identifying therapeutic targets within the critical immune and inflammatory pathways associatedwith the development and progression of disease (Nickoloff & Nestle, 2004).”
BackgroundStudy of Serum Leptin and Lipid Profile Concentration in Psoriatic Patients in Hilla - Iraq
Al-Hattab, M. K., Al-Gazally, M. E., & Al-Asadi, R. A. (2011) · Cited by 1
Vasar, E., Kingo, K., Silm, H., & Kõks, S. (2006) · CRC Press eBooks · doi:10.1201/9781420005325.ch22 · Cited by 1
The Roles of IL-22 and Its Related Family Members in the Pathogenesis of Psoriasis
Valdez, P. A., & Ouyang, W. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9371-7_24 · Cited by 1
Газиев, А. Р., OSLOPOV, V. N., Альфредович, Ш. Б., Minullin, I. K., Сафина, Ф. Г., Егорова, О. В., Муратович, В. Х., Чугунова, Д. Н., & Andrianova, O. N. (2013) · CyberLeninK (CyberLeninka) · Cited by 1
Ibrahim, D. A., & Khattab, F. M. (2016) · Egyptian Journal of Pathology · doi:10.1097/01.xej.0000508555.81922.f5 · Cited by 1
“In addition, some studies have reported that several growth factors and cytokines that are upregulated in psoriasis, such as IL-6, IL-10, and IL-20 family cytokines, are able to induce STAT3 activation.”
BackgroundFrers, R. A. K., Losada, M. E. O., Herrera, M. I., Porta, S., Cosentino, V. L., Kerzberg, E. M., Udovin, L., & Capani, F. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.89230 · Cited by 2
Pro-inflammatory IL-1 and TNF alpha cytokines in affected skin foci in psoriatic patients
Katunina, O. R., Rezaykina, A. V., Katunina, O. R., & Rezaikina, A. V. (2011) · Vestnik dermatologii i venerologii · doi:10.25208/vdv1031 · Cited by 1
Jullien, D., & Staumont-Sallé, D. (2019) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2019.04.014 · Cited by 1
Shenoy, C., Shenoy, M., Shantaram, M., Shetty, S., Nair, N. B., & Shankar, A. A. (2016) · Manipal Journal of Medical Sciences · doi:10.55889/2582-5984.1007 · Cited by 1
Behandlungsstrategien bei Psoriasis vulgaris und Psoriasisarthritis
Wozel, G. (2009) · Der Hautarzt · doi:10.1007/s00105-008-1662-4 · Cited by 1
Lynde, C. W. (2005) · Journal of Cutaneous Medicine and Surgery · doi:10.1007/s10227-006-0100-4 · Cited by 1
MMP/ADAM inhibitors: therapeutic potential for psoriasis
Yokota, K., & Nishimura, S. (2005) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.15.4.421 · Cited by 1
“The formation, as well as persistence, of psoriatic skin lesions is associated with skin infiltration by immune cells [2].”
BackgroundEffector Function of CLA+ T Lymphocytes on Autologous Keratinocytes in Psoriasis
Ferrán, M., Giménez‐Arnau, A. M., Bellosillo, B., Pujol, R. M., & Santamaria‐Babí, L. F. (2008) · Actas Dermo-Sifiliográficas · doi:10.1016/s1578-2190(08)70346-9 · Cited by 1
Development of an interleukin 2 receptor targeted gene therapy vehicle
Wattanakaroon, W. (2006) · OakTrust (Texas A&M University Libraries) · Cited by 1
Efeitos do óleo da semente do maracujá na psoríase experimental
Alvarenga, A. C. M. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2018.tde-18072018-150950 · Cited by 1
Zehn Jahre Biologics in der Dermatologie
Wozel, G., & Meurer, M. (2012) · Der Hautarzt · doi:10.1007/s00105-011-2296-5
New Treatments for Psoriasis and Atopic Dermatitis
Elices, M. J., & Arrhenius, T. S. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00237-6
Periodontal manifestations in a patient with psoriasis: A case report
Kranti, K., Mani, R., & Begaum, S. (2013) · International Journal of Case Reports and Images · doi:10.5348/ijcri-2013-07-334-8
“This has been attributed to the common inflammatory pathways with similar pathogenic mechanism, involving cytokine dysregulation in psoriasis and several associated diseases such as arthritis, diabetes, cardiovascular disease and irritable bowel syndrome which are referred to as immune mediated inflammatory diseases […”
BackgroundUSE OF BIOLOGICAL AGENTS AT UNIVERSITY CLINICAL CENTER MARIBOR
Bavec, A., & Krajnc, I. (2008) · Slovenian Medical Journal
Mast cells in chronic inflammatory diseases : New insights in mast cell function and phenotype
Carvalho, D. S., & Filipe, R. (2008) · Figshare
Psoriasis og kosthold i Nord-Norge
Myklatun, M. K. (2012) · NORA - Norwegian Open Research Archives
Le rhumatisme psoriasique : une spondylarthropathie méconnue
Combe, B. G. (2007) · Revue du Rhumatisme · doi:10.1016/s1169-8330(07)78642-8
Role of cytokine therapy in the treatment of psoriasis
Zheng, Y., Caro, I., & Ouyang, W. (2007) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2007.08.001
Es necesario el control de la psoriasis a largo plazo
Carazo, J. L. S., Casimiro, L. M., & de Miguel, V. A. (2008) · Actas Dermo-Sifiliográficas · doi:10.1016/s0001-7310(08)76196-9
A review of recent journal highlights
Barker, J. N. (2004) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2004.01622.x
Carvalho, S., Torres, T. R., & Selores, M. (2013) · Journal of the Portuguese Society of Dermatology and Venereology · doi:10.29021/spdv.70.3.5
Stem cell transplantation in rheumatic diseases
Brooks, P., Moore, J. J., & Tyndall, A. (2003) · APLAR Journal of Rheumatology · doi:10.1046/j.0219-0494.2003.00030.x
“of AS: ( 1 ) the arthritogenic peptide hypothesis; (2) HLA-B27 homodimer formation; (3) alteration of”
BackgroundLYMPHOCYTE APOPTOSIS IN PSORIASIS
Капулер, О. М., Nelyubin, Е. V., Kaut, D. A., & Sibiryak, S. V. (2014) · Medical Immunology (Russia) · doi:10.15789/1563-0625-2006-4-531-538
Al‐Ajmi, H., Abu-Elela, M. A., Al-Enezi, M. H., Mustafa, A.-M. M., Al-Enezi, S. K., & Abdulkader, A. (2010)
Duarte, G. V., Follador, I., Cavalheiro, C. M. A., & Silva, T. S. (2010)
ONICOMICOSE E PSORÍASE UNGUEAL
Silva, P. M. M. G. D. C., & Velho, G. (2015) · Journal of the Portuguese Society of Dermatology and Venereology · doi:10.29021/spdv.73.2.367
Lise, M. L. Z. (2015) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Expression of toll-like receptor-2 in psoriasis
Kawy, F. A. A. E., Azeem, A. A. A. E., El-Aziz, G. A. A., Yahea, R., & El-Badawy, N. (2012) · Journal of the Egyptian Womenʼs Dermatologic Society · doi:10.1097/01.ewx.0000413052.47404.a1
Association of insulin-like growth factor-1 gene polymorphism with psoriasis
Hamid, M. F. A., Sayed, K. S., Mohammed, F. N., Saei, M. L., & Amr, K. S. (2014) · Journal of the Egyptian Womenʼs Dermatologic Society · doi:10.1097/01.ewx.0000444267.97380.3e
Comorbidities, Metabolic and Malignancy Risk Profile in Patients with Psoriasis
Husein‐ElAhmed, H., Molina‐Leyva, A., la Fuente, G. C.-D., & Castillo, R. F. (2016) · West Indian Medical Journal · doi:10.7727/wimj.2015.454
Al-Kudwah, A. J., & Feldman, S. R. (2009) · Southern Medical Journal · doi:10.1097/smj.0b013e3181a59c4f · Cited by 1
“The frequency of squamous cell carcinoma (SCC) is increased, dramatically so in patients who have previously received extensive photochemotherapy.(41,42)”
BackgroundPathomechanisms underlying the psoriasiform skin disease in CD18 hypomorphic PL/J mice
Wang, H. (2006) · OPen Access Repositorium der Universität Ulm (OPARU) (Ulm University) · doi:10.18725/oparu-781
“By using genome-wide scans, investigators have mapped at least six different susceptibility loci, designated PSORS1–PSORS6 (1).”
BackgroundInfluentialKas bioloogilised ravimid toovad paradigma muutuse psoriaasi ravis?
Volke, A. (2014) · Ajakirjad. Journals by UT · doi:10.15157/ea.v0i0.10195
Evaluating the Interleukin 17 Serum Level in Psoriatic Patients from Eastern Egyptian Population
Elmajd, Y. A., Ibrahim, H., Raafat, N., & Mawla, Y. A. (2011) · Indian Journal Of Applied Research · doi:10.15373/2249555x/july2014/206
Metadata
- Authors
- Nickoloff, B. J., & Nestle, F. O.
- Affiliations
- Loyola University Medical Center (US)
- University of Zurich (CH)
- Corresponding author
- Nickoloff, Brian J.
- Venue
- Journal of Clinical Investigation
- Published
- 2004-06-15
- Volume
- 113
- Issue
- 12
- Pages
- 1664-1675
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC420513
- OpenAlex
- W2024387258
- Cited by
- 544
- References
- 110
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 9 · 2023: 11 · 2022: 23 · 2021: 18 · 2020: 10 · 2019: 23 · 2018: 18 · 2017: 17 · 2016: 19 · 2015: 24 · 2014: 26 · 2013: 29 · 2012: 27
- FWCI
- 19.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Doris Duke Charitable Foundation
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR40065, R01AR040065)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- psoriasis, immunopathogenesis, T cells, immunological synapse, cytokine signaling pathways, xenotransplantation model, targeted therapy, psoriasis genetics, chronic skin inflammation, psoriatic arthritis
- MeSH terms
- Animals, Dermatologic Agents, Disease Models, Animal, Disease Susceptibility, Humans, Immune System, Psoriasis, T-Lymphocytes, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.